CITIUS ONCOLOGY, INC. (CTOR): debt financing — TenX Keane extends business combination deadline to Oct 18, 2023 with $660k deposit

CITIUS ONCOLOGY, INC.

Deposited $660k ($0.10 per public share) into trust to extend business combination deadline.
Deadline extended from July 18, 2023 to October 18, 2023.
Sponsor 10XYZ Holdings LP provided funds via unsecured promissory note.
Note convertible up to $1.5M into private units at $10/unit upon business combination.
Extension is first of up to three possible 3-month extensions.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CITIUS ONCOLOGY, INC. incurred convertible notes of $660,000 with 10XYZ Holdings LP at bears no interest maturing upon the consummation of the Company's business combination.

Instrument: convertible notes
Principal: $660,000
Counterparty: 10XYZ Holdings LP
Rate: bears no interest
Maturity: upon the consummation of the Company's business combination
Event: incurrence

Exact text from the filing

On July 18, 2023, the Company deposited $660,000 into the trust account of the Company (the “Extension Fee”) to extend the timeline to complete a business combination for an additional three months from July 18, 2023 to October 18, 2023 (the “Extension”). Such deposit of the Extension Fee is evidenced by an unsecured promissory note (the “Promissory Note”) in the principal amount of $660,000 to the Sponsor. The Promissory Note bears no interest and is payable in full upon the consummation of the Company’s business combination (such date, the “Maturity Date”).

View on SEC.gov

7 debt financings filed in the last 30 days. Browse all debt financings →

CITIUS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-024835

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.